PhLP inhibitors, or Pleckstrin Homology Domain and Leucine-Rich Repeat Protein Phosphatase inhibitors, constitute a class of chemical compounds designed to modulate the activity of a specific group of proteins known as PhLPPs. PhLPPs are phosphatases that play a pivotal role in cellular signaling pathways by dephosphorylating critical signaling molecules, primarily members of the Akt (protein kinase B) family. Akt proteins are central to numerous cellular processes, including cell survival, proliferation, metabolism, and growth. PhLP inhibitors, by their mechanism of action, aim to interfere with the catalytic activity or substrate recognition of PhLPPs, ultimately affecting the phosphorylation status and activity of Akt and other downstream effectors in these signaling cascades.
The mechanism of action of PhLP inhibitors typically involves the selective binding and inhibition of PhLPPs, primarily PhLPP1 and PhLPP2. These inhibitors are designed to disrupt the phosphatase activity of PhLPPs, blocking them from removing phosphate groups from their substrates, such as Akt. This, in turn, leads to the sustained phosphorylation and activation of Akt and downstream signaling molecules. Some PhLP inhibitors achieve this by directly binding to the catalytic domains of PhLPPs, while others may disrupt the interaction between PhLPPs and their substrates, inhibiting dephosphorylation. The result is enhanced signaling through Akt-dependent pathways, which can have profound implications for various cellular functions and responses.PhLP inhibitors have become valuable tools in cell biology research, allowing scientists to dissect and understand the intricate signaling networks governed by Akt and its regulators. These inhibitors help elucidate the roles of PhLPPs in different cellular contexts and uncover targets. Their specificity for PhLPPs and their ability to modulate Akt activity make them indispensable for studying the molecular mechanisms underlying diverse physiological and pathological processes, without necessarily delving into applications.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A66 | 1166227-08-2 | sc-364394 sc-364394A | 5 mg 50 mg | $255.00 $1455.00 | ||
A66 is a small molecule inhibitor that selectively targets PHLPP1 and PHLPP2 by binding to their catalytic domains. This interaction prevents PHLPP-mediated dephosphorylation of Akt, leading to increased Akt activity in cell signaling pathways. | ||||||